FY2025 · ended Aug 31, 2025 · Revenue $705,923, +52.0% YoY · Filed Nov 28, 2025
Lexaria Bioscience Corp. (LEXX) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2025, which ended Aug 31, 2025, it reported revenue of $705,923 and a net loss of $11.9 million. Free cash flow was -$10.5 million. As of May 31, 2026 it held $3.5 million in cash and investments and $86,714 in total debt.
Revenue (TTM)
$194,000
-68.5% vs year-ago TTM
Net income (TTM)
$-7.73M
+32.1% vs year-ago TTM
Operating cash flow (TTM)
$-7.43M
+23.4% vs year-ago TTM
Free cash flow (TTM)
$-7.47M
+23.6% vs year-ago TTM
EPS (TTM)
$-0.34
Dividend per share
None
Shares outstanding
22.23M
+27.3% vs prior year
Net cash
$3.41M
as of May 31, 2026
Operating margin
-3973.2%
FY 2026
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- LEXX (Nasdaq)
- Fiscal year ends
- August 31
- Incorporated in
- NV
- Headquarters
- Kelowna, British Columbia, Canada
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1348362
- Former names
- Lexaria Corp. (until May 11, 2016); LEXARIA CORP. (until May 11, 2016)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Aug 31, 2025 |
FY 2024 Aug 31, 2024 |
FY 2023 Aug 31, 2023 |
FY 2022 Aug 31, 2022 |
FY 2021 Aug 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $705,923 | $464,278 | $226,208 | $255,397 | $722,738 |
| Operating income | -$11.9M | -$5.8M | -$6.5M | -$6.6M | — |
| Net income | -$11.9M | -$5.8M | -$6.7M | -$7.3M | -$4.0M |
| Diluted EPS | -$0.66 | -$0.47 | — | — | — |
| Operating cash flow | -$10.5M | -$5.0M | -$5.9M | -$4.9M | -$4.0M |
| Free cash flow | -$10.5M | -$5.0M | -$5.9M | — | — |
| Total assets | $4.2M | $8.9M | $3.1M | $7.8M | $13.3M |
| Total liabilities | $1.6M | $1.2M | $403,908 | $201,437 | $203,265 |
| Stockholders' equity | $3.0M | $8.0M | $3.0M | $7.9M | $13.3M |
| Cash and investments | $2.2M | $6.6M | $1.5M | $6.2M | $11.8M |
| Total debt | $109,319 | $137,366 | $163,967 | $49,988 | $39,404 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Material agreement, Unregistered share sale, Regulation FD disclosure
|
Sep 9, 2026 | Sep 7, 2026 |
| 8-K |
Current report
Other events
|
Sep 1, 2026 | Aug 28, 2026 |
| 8-K |
Current report
Other events
|
Aug 17, 2026 | Aug 17, 2026 |
| 8-K |
Current report
Listing notice
|
Aug 10, 2026 | Aug 4, 2026 |
| 8-K |
Current report
Change to shareholder rights, Bylaw or fiscal year change
|
Jul 30, 2026 | Jul 29, 2026 |
| 10-Q | Quarterly report | Jul 13, 2026 | May 31, 2026 |
All 1000 Lexaria Bioscience Corp. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.